According to the report published by the Market Research Store, global demand for the Acute Pancreatitis Treatment market was estimated at approximately USD 5,018.3 Million in 2020 and is anticipated to generate revenue of around USD 7,081.7 Million by end of 2026, growing at a CAGR of around 6.23% between 2021 and 2026.
The term acute pancreatitis is a sudden inflammation in the pancreas due to numerous causes in the body together with gallstone, systemic disease, and use of heavy alcohol. Generally, gallstones produces about 40% of cases of acute pancreatitis. With the help of short-term hospitalization treatment, mild acute pancreatitis can be treated. In case of severe acute pancreatitis, patients need hospitalization for a longer period of time where they are likely to give intravenous fluids or admitted to the ICU for additional treatment.
| REPORT SNAPSHOT & REPORTING DATA TIMEFRAME | |
|---|---|
| Parameter | Details |
| Historical Date ( Actual Data) | 2016 - 2020 |
| Base Year Data | 2020 |
| Current Year Data | 2021 |
| Projected Data | 2021 - 2026 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | product type, application, region |
| Regional scope | North America; Europe; Asia Pacific; Central & South America; Middle East & Africa |
| Country Scope | U.S.; Canada; Mexico; Germany; France; U.K.; China; Japan; South Korea; Singapore; Malaysia; Brazil; Saudi Arabia |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Due to the Increase in cases of obesity and gallstones the occurrence of acute pancreatitis patient is rising across the world. According to WHO, 39% of adults aged 18 years and above were overweight in 2016. Overall, about 13% of the world's adult population (15% of women and 11% of men) was obese in 2016. The incidence of obesity nearly tripled between 1975 and 2016 across the world. Prevalence of acute pancreatitis was reported from 17 countries across Europe and ranged from 4.6 to 100 per 100 000 population. Prevalence was usually elevated in eastern or northern Europe. Currently, acute pancreatitis is a highly common cause for hospitalization of a gastrointestinal related disease in the U.S. Presently, acute pancreatitis is a specifically usual cause for the hospitalization of a gastrointestinal related disease. Moreover, increasing awareness and advancements of essential devices and instruments is another factor stimulating the market growth. Also, increasing investment in healthcare sector will boost the market.
However, poor recovering policies for the treatment of this disorder may hinder the market growth.
On the basis of type, the global acute pancreatitis treatment market is segmented into drug therapy, device based therapy and others. The drug-based therapy segment can be further divided into antibiotics, analgesics, and others and the device based therapy can be segmented into endoscopic retrograde cholangiopancreatography (ERCP), intravenous fluid, and surgery. The others segment can be segregated into antioxidant therapy, nutritional support, and others.
Further the market for acute pancreatitis treatment, the end user industry is classified into hospitals, antioxidant therapy and others.
North America is dominating the acute pancreatitis treatment in terms of revenue followed by Europe. The reported yearly prevalence of acute pancreatitis in the U.S. ranges from 4.9 to 35 per 100,000 population. Moreover, the market in Asia Pacific is expected to grow at crucial CAGR during the forecast period. Furthermore, the increasing investment in healthcare sector in specific region enhances the market. In Japan, the approximated number of patients with AP showed a 1.8-fold growth in the last decade. In 2015, according to a survey published in NCBI, the incidences in Japan was 49.4 per 100,000 population.
Major key industries in global acute pancreatitis treatment market include, Samsung Bioepis, AstraZeneca, Pfizer, GNT Pharma, CalciMedica, B. Braun Melsungen, General Electric Company, Abbott Pharmaceutical, Fresenius Kabi USA, Sun BioPharma, GlaxoSmithKline, Novartis, Boston Scientific Corporation, SCM Lifescience, and Medtronic.
Due to the Increase in cases of obesity and gallstones the occurrence of acute pancreatitis patient is rising across the world. Presently, acute pancreatitis is a specifically usual cause for the hospitalization of a gastrointestinal related disease. Moreover, increasing awareness and advancements of essential devices and instruments is another factor stimulating the market growth. Also, increasing investment in healthcare sector will boost the market.
The acute pancreatitis treatment is expected to grow at a significant CAGR during the forecast period due to the essential products and the increase in investment of pharmaceutical companies.
North America is dominating the acute pancreatitis treatment in terms of revenue followed by Europe. Moreover, the market in Asia Pacific is expected to grow at crucial CAGR during the forecast period.
Major key industries in global acute pancreatitis treatment market include CalciMedica, SCM Lifescience, Samsung Bioepis, GNT Pharma Co, AstraZeneca, B. Braun Melsungen AG, General Electric Company, Medtronic, Abbott Laboratories, Sun BioPharma, Inc, Boston Scientific Corporation, Fresenius Kabi USA, GlaxoSmithKline, Novartis AG, and Pfizer.
Acute Pancreatitis Treatment
Acute Pancreatitis Treatment
×